...
首页> 外文期刊>Trials >Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial
【24h】

Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial

机译:与阿托伐他汀相比,高剂量硒匹伐他汀对代谢综合征(LESS-DM)患者的致糖尿病作用具有长期影响:一项随机对照研究的研究方案

获取原文

摘要

The diabetogenic action of statins remains a concern, particularly in patients at high risk for diabetes receiving intensive statin therapy. Despite the risk of diabetes with statin use being considered a potential class effect, recent studies have suggested that pitavastatin exerts neutral or favorable effects on diabetogenicity. However, no randomized trial has compared the long-term effects of pitavastatin with those of other statins on glycemic control in populations at high risk for diabetes. Hence, we aim to assess the long-term effects of pitavastatin in comparison with atorvastatin on glucose metabolism in patients with metabolic syndrome (MetS). The Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM) trial is a prospective, randomized, open-label, active control clinical trial of patients with MetS. We plan to randomize 500 patients with MetS (1:1) to receive high-dose pitavastatin (4?mg) or atorvastatin (20?mg) daily for 24?months. The primary endpoint will be the change in hemoglobin A1c after statin treatment. Secondary endpoints will include the following: (1) changes in biochemical markers, including insulin, C-peptide, homeostasis model assessment of insulin resistance and insulin secretion, and adiponectin; (2) changes in imaging parameters, including carotid elasticity metrics and indices of cardiac function; and (3) the incidence of clinical events, including new-onset diabetes and cardiovascular disease. In this trial, we will explore whether pitavastatin 4?mg does not disturb glucose metabolism in patients with MetS. It will also provide mechanistic information on statin type-dependent diabetogenic effects and surrogate data regarding vascular and cardiac changes achieved by intensive statin therapy. ClinicalTrials.gov, NCT02940366 . Registered on 19 October 2016.
机译:他汀类药物的致糖尿病作用仍然值得关注,特别是在接受强化他汀类药物治疗的糖尿病高危患者中。尽管使用他汀类药物被认为具有潜在的类别效应,但存在糖尿病风险,但最近的研究表明,匹伐他汀对糖尿病的形成具有中性或有利作用。但是,没有一项随机试验将匹伐他汀与其他他汀类药物对糖尿病高危人群的血糖控制的长期影响进行比较。因此,我们旨在评估匹伐他汀与阿托伐他汀相比对代谢综合征(MetS)患者葡萄糖代谢的长期影响。与代谢综合征患者中的阿托伐他汀相比,高剂量硒匹伐他汀对糖尿病的长期影响(LESS-DM)试验是一项针对MetS患者的前瞻性,随机,开放标签,主动对照临床试验。我们计划将500名MetS(1:1)患者随机分组,每天接受大剂量匹伐他汀(4?mg)或阿托伐他汀(20?mg),持续24个月。主要终点将是他汀类药物治疗后血红蛋白A1c的变化。次要终点包括:(1)生化指标的变化,包括胰岛素,C肽,对胰岛素抵抗和胰岛素分泌的稳态模型评估以及脂联素; (2)成像参数的变化,包括颈动脉弹性指标和心功能指标; (3)临床事件的发生率,包括新发糖尿病和心血管疾病。在该试验中,我们将探讨匹伐他汀4 mg是否不会干扰MetS患者的葡萄糖代谢。它还将提供有关他汀类药物依赖性糖尿病发生作用的机制信息,并提供有关通过他汀类药物强化治疗实现的血管和心脏变化的替代数据。 ClinicalTrials.gov,NCT02940366。 2016年10月19日注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号